Drug Trial Radar · NCT05690386
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Feb 15, 2023
Primary completion
Oct 18, 2024
Study completion Dec 2027
Sponsor
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/SIndustry
- Sponsor type
- Industry
- First posted
- Jan 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 1 year, up to 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 104 week dose finding open label trial followed by an optional 78 week open label extension of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus daily somatropin product in prepubertal individuals with Turner syndrome. Approximately 48 individuals (12 individuals per arm) will be randomized to receive one of three doses of lonapegsomatropin or a daily injection of somatropin. This is a trial that will be conducted in the United States.
Conditions
- Turner Syndrome
Interventions
LonapegsomatropinBiological
Once-weekly subcutaneous injection of Lonapegsomatropin
SomatropinDrug
Once-daily subcutaneous injection of Somatropin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Height Velocity (AHV) (cm/year)Time frame: 26 weeks
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Ascendis Pharma Investigational Site
Palo Alto, California
Ascendis Pharma Investigational Site
San Diego, California
Ascendis Pharma Investigational Site
Aurora, Colorado
Ascendis Pharma Investigational Site
Orlando, Florida
Ascendis Pharma Investigational Site
St. Petersburg, Florida
Ascendis Pharma Investigational Site
Atlanta, Georgia
Ascendis Pharma Investigational Site
Idaho Falls, Idaho
Ascendis Pharma Investigational Site
Chicago, Illinois
Ascendis Pharma Investigational Site
Boston, Massachusetts
Ascendis Pharma Investigational Site
Saint Paul, Minnesota
Ascendis Pharma Investigational Site
Las Vegas, Nevada
Ascendis Pharma Investigational Site
Lake Success, New York
Ascendis Pharma Investigational Site
Chapel Hill, North Carolina
Ascendis Pharma Investigational Site
Cincinnati, Ohio
Ascendis Pharma Investigational Site
Oklahoma City, Oklahoma
Ascendis Pharma Investigational Site
Portland, Oregon
Ascendis Pharma Investigational Site
El Paso, Texas
Ascendis Pharma Investigational Site
Fort Worth, Texas
Ascendis Pharma Investigational Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.